102 related articles for article (PubMed ID: 16648510)
21. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
22. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer.
Eckhoff L; Knoop AS; Jensen MB; Ejlertsen B; Ewertz M
Breast Cancer Res Treat; 2013 Nov; 142(1):109-18. PubMed ID: 24132874
[TBL] [Abstract][Full Text] [Related]
23. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
[TBL] [Abstract][Full Text] [Related]
24. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
Bhushan S; Walko CM
Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
[TBL] [Abstract][Full Text] [Related]
25. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.
Aogi K; Rai Y; Ito Y; Masuda N; Watanabe J; Horiguchi J; Tokudome T; Takashima S
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1427-33. PubMed ID: 23536163
[TBL] [Abstract][Full Text] [Related]
28. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
Abraham J; Agrawal M; Bakke S; Rutt A; Edgerly M; Balis FM; Widemann B; Davis L; Damle B; Sonnichsen D; Lebwohl D; Bates S; Kotz H; Fojo T
J Clin Oncol; 2003 May; 21(9):1866-73. PubMed ID: 12721265
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
Forsyth PA; Balmaceda C; Peterson K; Seidman AD; Brasher P; DeAngelis LM
J Neurooncol; 1997 Oct; 35(1):47-53. PubMed ID: 9266440
[TBL] [Abstract][Full Text] [Related]
31. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
[TBL] [Abstract][Full Text] [Related]
33. Advances in breast cancer treatment: the emerging role of ixabepilone.
Frye DK
Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
[TBL] [Abstract][Full Text] [Related]
34. Ixabepilone: clinical role in metastatic breast cancer.
Denduluri N; Swain S
Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
[TBL] [Abstract][Full Text] [Related]
35. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.
Eckhoff L; Knoop A; Jensen MB; Ewertz M
Eur J Cancer; 2015 Feb; 51(3):292-300. PubMed ID: 25541155
[TBL] [Abstract][Full Text] [Related]
36. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
37. Dermatological toxicity of ixabepilone.
Conlin AK; Vahdat L
Anticancer Res; 2006; 26(3B):2279-80. PubMed ID: 16821602
[TBL] [Abstract][Full Text] [Related]
38. Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.
Bosch-Barrera J; Espinós J; Gómez-Ibáñez A; Gállego Pérez-Larraya J; Iriarte J
Clin Transl Oncol; 2009 Nov; 11(11):765-7. PubMed ID: 19917541
[TBL] [Abstract][Full Text] [Related]
39. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
40. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
